StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
REVBL.XC$3.70+1.09%
Fair $3.70+0.0%

REVBL.XC

Revolution Beauty Group plc

Consumer Defensive / Household & Personal ProductsCboe UK

$3.70

+0.04 (+1.09%)

Fairly Valued+0.0%Fair Value $3.70Fund rank 27/100 · Data gapFallback financials|
SA 17/F
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $1.2M · quality 47.0/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 16/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

17/100

F

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 1.0%, below the 5% threshold
Thesis & Journal · REVBL.XCLocal privado en este navegador · Revolution Beauty Group plc
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$32M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

101.0%

↑

Gross Margin

38.2%

↑

Debt/Equity

-1.95

↓
52-Week Range$4
$0$5

TradingView lightweight chart

REVBL.XC price, volumen y niveles de valoración

Último $3.700Periodo -51.8%
Fair value: $3.700

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-8.2%

FCF CAGR

—

FCF margin

0.8%

FCF / Net income

-0.07x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $142.6M · net income $-17.2M · FCF $1.2M

2022-FY → 2025-FY

Gross margin

38.2%-0.3% pts

Operating margin

-8.0%-0.7% pts

Net margin

-12.1%+11.9% pts

FCF margin

0.8%+15.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$142.6M$142.6M$191.3M$187.8M$184.6M
Net Income$-17.2M$-17.2M$10.7M$-33.6M$-44.3M
EBITDA$-7.9M$-7.9M$19.7M$-20.3M$-32.2M
EPS-0.05-0.050.03-0.11-0.16
Gross Margin38.2%38.2%46.2%40.4%38.5%
Operating Margin-8.0%-8.0%3.0%-12.6%-7.3%
Net Margin-12.1%-12.1%5.6%-17.9%-24.0%
Balance Sheet
Debt/Equity-1.95-1.95203.15-2.641.38
Current Ratio0.580.58———
Cash Flow
Free Cash Flow$1.2M$1.2M$2.0M$-8.6M$-26.8M
Returns
ROE101.0%101.0%6011.2%256.2%-216.9%
Growth & Yield
Revenue Growth-25.5%-25.5%1.8%1.8%—
EPS Growth-268.7%-268.7%129.4%30.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +5074.8%

Total return

+5074.8%

Start / end P/E

n/dx → n/dx

EPS bridge

0.03 → -0.05

Residual

+5074.8%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+5074.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.